New Jersey 2024-2025 Regular Session

New Jersey Assembly Bill A4677

Introduced
6/28/24  

Caption

Increases amount of cigarette and other tobacco products tax revenues provided to New Jersey Commission on Cancer Research to $10 million; establishes dedicated, non-lapsing Cancer Research Fund.

Impact

The establishment of the Cancer Research Fund within the Department of the Treasury marks a critical shift in how cancer research is funded in New Jersey. By ensuring that at least $5 million is explicitly earmarked for pediatric cancer research and another $5 million for general cancer research, the bill directly addresses both the breadth and depth of cancer issues affecting various populations. It aims to enhance access to high-quality cancer care and research for minority and vulnerable communities in the state. This approach is likely to increase participation in clinical trials and research funding focused on reducing health disparities related to cancer.

Summary

Assembly Bill A4677 proposes to increase the annual allocation of cigarette and other tobacco products tax revenues to the New Jersey Commission on Cancer Research (NJCCR) from $1 million to $10 million. This significant increase aims to provide essential funding for various cancer research initiatives, allowing for a more robust approach to studying cancer causes, prevention, treatment, and care. The bill establishes a dedicated, non-lapsing Cancer Research Fund, ensuring that these resources are not subject to the annual appropriations act, which historically has redirected available funds away from the NJCCR to the General Fund for other uses.

Contention

Despite the benefits outlined in the bill, there could be contention regarding the use of tobacco tax revenues. Some stakeholders may argue against allocating these funds for cancer research rather than utilizing them for preventive health programs or cessation initiatives. Additionally, while the NJCCR has historically received limited funding, recent appropriations controversies may provoke debates about ensuring sustainable funding channels and accountability for cancer research expenditures. Opponents might question the efficiency of funneling more tax revenue into a system perceived as bureaucratic or poorly managed, calling for a transparent framework on fund allocation and outcomes.

Companion Bills

NJ S664

Same As Increases amount of cigarette and other tobacco products tax revenues provided to New Jersey Commission on Cancer Research to $10 million; establishes dedicated, non-lapsing Cancer Research Fund.

NJ S929

Carry Over Increases amount of cigarette and other tobacco products tax revenues provided to New Jersey Commission on Cancer Research to $10 million; establishes dedicated, non-lapsing Cancer Research Fund.

NJ A2869

Carry Over Increases amount of cigarette and other tobacco products tax revenues provided to New Jersey Commission on Cancer Research to $10 million; establishes dedicated, non-lapsing Cancer Research Fund.

Similar Bills

HI SB2674

Relating To Energy.

HI HB2054

Relating To Energy.

HI HB1257

Relating To Energy.

HI SB1518

Relating To Energy.

CA AB700

California Firefighter Cancer Prevention and Research Program.

HI SB3205

Relating To Energy.

CA AB829

California Neurodegenerative Disease Registry program: Parkinson’s Disease Research Voluntary Tax Contribution Fund.

CA SB829

California Institute for Scientific Research: CalRx Initiative: vaccines.